论文部分内容阅读
目的观察低分子肝素联合降纤酶治疗急性脑梗死的临床疗效。方法选择急性脑梗死患者122例,随机分为对照组和治疗组,对照组给予川芎嗪、低分子肝素治疗,治疗组在对照组基础上加降纤酶治疗。两组均于治疗前及治疗后14 d进行神经功能缺损评分,并观察不良反应。结果治疗14 d后神经功能缺损评分、总有效率对照组分别为(11.5±3.7)分、75.00%,治疗组分别为(7.2±3.3)分、91.94%,两组比较差异均有统计学意义(均P<0.05)。结论低分子肝素联合降纤酶治疗急性脑梗死疗效好,且无严重不良反应,值得临床推广应用。
Objective To observe the clinical effect of low molecular weight heparin combined with defibrase on acute cerebral infarction. Methods 122 patients with acute cerebral infarction were randomly divided into control group and treatment group. The control group was given ligustrazine and low molecular weight heparin. The treatment group was treated with defibrase on the basis of control group. Neurological impairment scores were observed before treatment and 14 days after treatment in both groups, and adverse reactions were observed. Results After 14 days of treatment, the neurological deficit score and total effective rate were (11.5 ± 3.7) and 75.00% in the control group and (7.2 ± 3.3) and 91.94% in the treatment group respectively, with significant differences between the two groups (All P <0.05). Conclusion Low molecular weight heparin combined with defibrase in the treatment of acute cerebral infarction has good curative effect and no serious adverse reactions, which is worthy of clinical application.